TIDMRENE
RNS Number : 3423Z
ReNeuron Group plc
14 September 2022
ReNeuron Group plc
("ReNeuron" or the "Company" or the "Group")
Directorate and Executive Changes
Appointment of Chief Financial Officer and Chief Business
Officer
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell
derived exosome technologies, announces the appointment of John
Hawkins, ACA, as Chief Financial Officer ('CFO') and ReNeuron Board
member with immediate effect. The Group is also pleased to announce
that Simon Dew will be joining the Executive Team as Chief Business
Officer ('CBO').
Mr. Hawkins joined ReNeuron in October 2014 as Financial
Controller and was also appointed Company Secretary in June 2021.
Mr Hawkins is an experienced finance professional with a breadth of
experience gained within a variety of businesses, from large PLCs
to family-owned SMEs. Mr Hawkins graduated from university with a
1st class honours degree in industrial chemistry and started his
career with KPMG, where he qualified as a Chartered Accountant and
worked for the initial part of his career.
Mr. Dew is a senior healthcare executive with extensive
experience in Business Development and Corporate Strategy. His
career spans working at SmithKline Beecham, IQVIA, Astellas Pharma,
Gyroscope and more recently exosomes company Evox Therapeutics,
where he was responsible for leading two transformational
partnership deals with global pharmaceutical companies.
Additionally, the Group is making changes to the Executive team.
With immediate effect, Dr. Randolph Corteling assumes the role of
Chief Scientific Officer ('CSO') with Prof. Stefano Pluchino moving
to the role of Chair of the Scientific Advisory Board, continuing
to combine working with ReNeuron and his academic work in Exosomes
and Regenerative Neuroimmunology at the University of Cambridge.
Suzanne Hancock, currently Head of Operations, who has worked with
the Group since 2017, moves to the position of Chief Operations
Officer ('COO').
Iain Ross, Non-Executive Chairman, commented " I am delighted to
announce John Hawkins' appointment as CFO and a director of the
Company and also to welcome Simon Dew as member of the Executive
team. I believe under Catherine's leadership we have a strong
executive team in place to execute our plans."
Catherine Isted, Chief Executive Officer, commented : "I am
delighted John has accepted the position of CFO. He has been a key
part of the team redefining the operational and strategic focus of
the Group and his extensive knowledge of the business and tireless
work ethic have been invaluable especially in this period of
transition.
"The appointment of Simon Dew as CBO will be a key role in the
new ReNeuron Executive team to maximise the opportunity we see
ahead of us in the field and to accelerate our partnership
opportunities. We are delighted to have been able to attract a
candidate of such high calibre and experience, especially in the
field of exosomes, to join the Group.
"With the other Executive changes announced today, I believe we
have the right team in place to deliver on the full potential that
our customisable Exosomes platform has to offer to biotech and
pharma partners and ultimately deliver value to our shareholders as
we build ReNeuron into the sustainable growing and commercially
validated business we know it can become."
The following information is disclosed in respect of John
Hawkins pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies.
The names of all companies and partnerships of which John
Michael Hawkins, aged 56, has been a director or partner at any
time in the previous five years are set out below:
Current directorships or partnerships Previous directorships or partnerships
86 Cathedral Road Rtm Company N/A
Limited
--------------------------------------
John Hawkins holds options over 340,000 ordinary shares of
ReNeuron. Save as set out in this announcement, there are no
further details to be disclosed under Rule 17 or Schedule 2(g) of
the AIM Rules for Companies in respect of John Hawkins.
ENDS
The person responsible for arranging for the release of this
announcement on behalf of the Company is
Catherine Isted, Chief Executive Officer.
Contacts:
ReNeuron Group plc www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
Catherine Isted, Chief Executive Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3100 2000
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve / George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus / Alice Woodings 804 654
About ReNeuron
ReNeuron is a UK based leader in Proprietary Stem Cell derived
Exosome Technologies company, harnessing its unique stem cell
technologies to develop 'off the shelf' treatments for diseases
with significant unmet needs.
ReNeuron's stem cell derived proprietary Exosome Technology
platform offers a delivery mechanism for a variety of payloads such
as siRNA, mRNA, proteins, small molecules and genes. The Group has
a growing number of partner collaborations with Global Pharma,
Biotech and academic partners in this fast-expanding area of
scientific and commercial interest. ReNeuron also has the ability,
through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and
has the potential to produce exosomes with tissue specific
targeting ability.
The Group has out-licenced its CTX Programme for stroke
disability and hRPC programme in retinitis pigmentosa to Fosun in
China and is looking to out-licence both these programmes in other
territories.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUOVNRURUKAAR
(END) Dow Jones Newswires
September 14, 2022 02:02 ET (06:02 GMT)
Reneuron (AQSE:RENE.GB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Reneuron (AQSE:RENE.GB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024